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Abstract
Background: Phanerochaete sordida is a species of wood rotting fungus, which can degrade lignin, cellulose and
hemicellulose contained in wood and other hard-to-biodegrade organic substances. However, to date, there have
been no other reports demonstrating that P. sordida can infect humans.
Case presentation: A 66-year-old Japanese man presented for a mass increasing in size on his left thigh. He had
been suffering from rheumatoid arthritis for 18 years and chronic obstructive pulmonary disease for 20 years, for
which he was being treated with 5 mg/day prednisolone and 8 mg/week methotrexate. The mass resection was
performed two months later, and was diagnosed as malignant fibrous histiocytosis. However, a computed tomography
examination for tumor recurrence after surgery showed a newly emergent pulmonary nodule. We therefore decided to
resect the nodule by thoracoscopic procedure. Histopathological examination of the excised specimen showed that
the lesion was a granuloma, with necrotic tissue and clumping of Aspergillus-like hyphae. Therefore, the nodule was
diagnosed as a fungal infection and tissue specimens were cultured microbiologically. However, fungal growth
was not observed. We consequently performed genetic analysis using a broad-range polymerase chain reaction.
The 28S rRNA sequence demonstrated 100% homology with P. sordida using the NCBI BLAST program against
the GenBank DNA databases.
Conclusions: Using broad-range polymerase chain reaction, we identified P. sordida as the causative agent of a
pulmonary nodule. These findings indicate that P. sordida may be an additional opportunistic causative organism
of pulmonary infection in immunocompromised patients.
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Background
Over 300 species of fungi are regarded as pathogenic to
humans, with the number of fungal species reported to
cause opportunistic infections still increasing [1]. Not-
ably, no specific gene or phenotype has been identified
as a marker of pathogenicity in humans. Phanerochaete
sordida is a species of wood-rotting fungus distributed
worldwide [2]. This fungus belongs to the family of
white-rot fungi that have the ability to degrade the lignin,
cellulose and hemicellulose contained in wood. White-rot
fungi are often edible, including shiitake mushrooms
(Lentinus edodes), oyster mushrooms (Pleurotus ostreatus)
and king trumpet mushrooms (Pleurotus eryngii). En-
zymes found in white-rot fungi have been reported to
break down hard-to-degrade compounds such as dioxins.
Fungal enzymes are therefore also being assessed for
use in bioremediation. Although several P. sordida
related studies have been conducted, P. sordida is gene-
rally regarded as unable to induce diseases in humans
and animals.
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This report describes a patient with a pulmonary nodule
induced by P. sordida. To our knowledge, this is the first
report showing that P. sordida is pathogenic in humans.
Case presentation
A 66-year-old Japanese man became aware of a mass on
his left posterior surface in March 2014. Within a
month, the mass had increased in size, and he began to
experience left femoral pain. His symptoms gradually
worsened, and the mass was excised partially in May
2014. Histopathological investigation at that time re-
sulted in a diagnosis of malignant fibrous histiocytoma.
As computed tomography (CT) scans of the patient’s en-
tire body showed multiple pulmonary nodules, he was
referred to our hospital for further examination and
treatment.
The patient’s previous medical history included
rheumatoid arthritis for 18 years and chronic obstructive
pulmonary disease for 20 years, for which he was being
treated with 5 mg/day prednisolone and 8 mg/week
methotrexate. He was an ex-smoker, with a 60 pack-year
history, and had been treated for 5 years with 1.0 L/min
home oxygen therapy. He had a history of treatment
with the non-steroidal anti-inflammatory drug (NSAID)
loxoprofen.
On admission, the patient’s height was 164.5 cm and
his weight was 57.4 kg. His blood pressure was 128/
96 mmHg; his heart rate was 76 beats/min and regular;
his oxygen saturation was 97% while receiving 1.0 L/min
oxygen; and his body temperature was 35.6 °C. Physical
examination showed no remarkable findings, except for
the left femoral mass. Chest CT revealed an additional
nodule in the right apical portion of the lung, with no
change in size of the preexisting nodules (Fig. 1-a). All
the nodules were under 3 to 5 mm in size. Positron
emission tomography showed accumulation of fluoro-
deoxyglucose (SUVmax: 2.39) only in the nodule newly
identified on CT (Fig. 1-b).
The left femoral tumor was excised completely in July
2014. The patient’s postoperative course was uneventful.
Because postoperative chemotherapy was indicated only
if the newly developed nodule was a metastatic tumor,
he underwent diagnostic wedge resection of the right
upper lobe under video-assisted thoracoscopy in August
2014, with tissue samples obtained aseptically. However,
this procedure was not able to excise all lung nodules.
Macroscopic findings revealed a black node with a
yellowish white interior (Fig. 2-a). Histopathological
examination of the specimen showed that the lesion was
a granuloma, with necrotic tissue and clumping of
Aspergillus-like hyphae. Grocott’s staining and periodic
acid-Schiff (PAS) staining (Fig. 2-b, c, d) were performed.
The periphery of the granuloma showed fibrotic changes
and invasion of inflammatory cells, including lympho-
cytes, histiocytes and multinucleated giant cells. In
addition, the thin granuloma layer was surrounded by
necrotic tissue. There was no evidence of malignancy.
These findings indicated a granuloma caused by fungal
infection.
Tissue specimens were cultured microbiologically on
potato dextrose agar medium at 37 °C. However, fungal
growth was not observed, even after 4 weeks. Gene ana-
lysis using broad-range polymerase chain reaction (PCR)
was performed to identify the pathogen. The 28S rRNA
gene of stored tissue samples was amplified and se-
quenced. Analysis of the 28S rRNA gene of this speci-
men using the NCBI BLAST program comparing
against the NCBI GenBank DNA database revealed
100% homology to P. sordida. The patient was diagnosed
with pulmonary mycosis caused by P. sordida.
Because the nodule was not a metastasis of the malig-
nant tumor, the patient underwent localized postopera-
tive radiation therapy of his femoral region to prevent
local recurrence. As no antifungal drugs have been
tested against P. sordida, the patient is being carefully
monitored every 2 months. Currently, 6 months after
Fig. 1 Computed tomography (CT) and fluorodeoxyglucose positron emission tomography (FDG-PET) findings. a Chest CT, showing a pulmonary
nodule (arrow) in the right apical portion of the lung. b FDG-PET, showing accumulation of fluorodeoxyglucose in the pulmonary nodule (arrow)
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the lung surgery, there has been no evidence of exacer-
bation of lung nodules.
Discussion
P. sordida is a white-rot wood fungus, the only type of
microbe that can effectively degrade lignin, a key com-
ponent of wood. As they contain enzymes that degrade
lignin, white-rot fungi are utilized for bioremediation.
The YK-624 strain of P. sordida is one of a series of
strains collected on Yakushima Island, Japan, that is both
highly active and selectively degrades lignin [3]. To date,
P. sordida has not been reported to be pathogenic in
humans or animals. The US Centers for Disease Control
and Prevention has reported that P. sordida has a bio-
safety level of 1, indicating that this microbe does not
induce diseases in humans or animals [4].
Nevertheless, we found that this patient was infected
by P. sordida, probably because he was in an immuno-
compromised state. He had a long history of rheumatoid
arthritis and was being treated with prednisolone and
methotrexate. Moreover, he had been diagnosed with
malignant fibrous histiocytoma. Furthermore, he had a
20-year history of chronic obstructive pulmonary disease,
which may have caused airflow stasis in his lower respira-
tory airways. Being an ex-smoker and on home oxygen
therapy may also have contributed to infection with this
normally non-pathogenic fungus. P. sordida has been
shown to metabolize the NSAIDs, diclofenac and mefe-
namic acid [5], a biochemical property that can contribute
to the establishment of local P. sordida infections in
humans. That is, the metabolism of NSAIDs at local infec-
tion sites can enhance the growth of P. sordida by sup-
pressing the local inflammatory reaction of host immune
cells.
P. sordida is unable to grow at the normal human
body temperature of 37 °C. If this fungus is aspirated
and migrates to the bronchial membrane in patients
with chronic obstructive pulmonary disease, P. sordida
may be able to grow slowly but not over a certain size.
P. sordida infection in humans may therefore be charac-
terized by small-sized nodules on CT images and slight
granuloma reactions in situ.
Histopathological examination and genetic analysis of
the pulmonary specimen resected from our patient re-
sulted in a diagnosis of pulmonary mycosis induced by
P. sordida. The inability to cultivate the fungus from the
Fig. 2 Histopathological findings of the pulmonary nodule in this patient. a Macroscopic examination of the nodule, showing a black node with a
yellowish white interior (arrow). b Periodic acid-Schiff (PAS) staining, showing a granuloma with clumping of hyphae. Fibrotic changes and invasion
of inflammatory cells are seen at the periphery of the granuloma (original magnification × 20). c PAS staining, showing a granuloma with necrotic
tissue and clumping of hyphae (original magnification × 40). d Grocott staining, showing septate hyphae (original magnification × 100)
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tissue specimen was likely due to the low viability of the
fungus or the presence in the tissue specimen of dead or
damaged fungi. In addition, the American Type Culture
Collection (ATCC) recommends that all the P. sordida
strains it provides be cultivated in potato dextrose agar
medium at 24 °C for approximately 4 weeks [6]. Dif-
ferences in temperature may result in unsuccessful
cultivation [7]. Notably, the temperature at which the
tissue specimen from this patient was cultured at
therefore differed from the ideal conditions. Thus, the
absence of other reports on the pathogenicity of P.
sordida may also be a result of cultivation under sub-
optimal conditions. Accordingly, genetic analysis may
enable identification when DNA can be collected, and
is very useful for identification of pathogens when cul-
tivation is unsuccessful.
To determine the antifungal susceptibility of this
strain, we obtained the reference strain P. sordida YK-
624 (ATCC 90872) and conducted an antifungal suscep-
tibility test using the microdilution method according to
the guidelines of the Clinical and Laboratory Standards
Institute (M38A). Although the growth of this strain was
observed in potato dextrose agar medium, it did not
form spores. Therefore, we could not complete the
susceptibility test. Subsequently, we conducted antifun-
gal susceptibility testing using the agar plate dilution
method with voriconazole and liposomal amphotericin
B. Voriconazole was active against this strain at concen-
trations ≥2.5 μg/mL. In contrast, 10 μg/mL liposomal
amphotericin B did not inhibit the growth of this strain.
Therefore, it may be necessary to establish a method for
antifungal susceptibility testing of filamentous fungi not
dependent on sporulation. Notably, at least for P. sordida
YK-624, voriconazole was found to have antimicrobial
activity. To our knowledge, there have been no previous
reports describing P. sordida infections in humans. Im-
portantly, if fungi cannot be cultivated, despite the pres-
ence of hyphae on histopathological examination and
smears, they may be successfully cultivated under different
conditions, or identified by genetic analysis.
Although the clinical significance of P. sordida infec-
tion has not been clarified, this fungus may be patho-
genic in humans. Assessment of additional infected
patients is required to determine the characteristics of
infection by this rare opportunistic pathogen. Currently,
we are still monitoring the patient’s lung nodules for an
increase in size or number. Fortunately, an increase in
lung nodules has not been seen thus far. However,
recurrence of opportunistic infections may occur fre-
quently in immunosuppressed patients. Until the anti-
fungal susceptibility is known, it is worth considering
the use voriconazole as an antifungal agent based on
the results of our susceptibility testing on a P. sordida
reference strain.
Conclusions
Using broad-range PCR, we identified P. sordida as the
causative agent of a pulmonary nodule in a patient. Our
case report indicates that P. sordida may be an additional
opportunistic causative organism of pulmonary infection
in immunocompromised patients. Importantly, molecular
methods may be helpful in identifying pulmonary P.
sordida infections in this patient population.
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